Caladrius Biosciences Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more
Caladrius Biosciences Inc. (0HS8) - Net Assets
Latest net assets as of September 2021: $98.67 Million USD
Based on the latest financial reports, Caladrius Biosciences Inc. (0HS8) has net assets worth $98.67 Million USD as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($102.54 Million) and total liabilities ($3.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $98.67 Million |
| % of Total Assets | 96.22% |
| Annual Growth Rate | 60.61% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 408.28 |
Caladrius Biosciences Inc. - Net Assets Trend (2016–2020)
This chart illustrates how Caladrius Biosciences Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Caladrius Biosciences Inc. (2016–2020)
The table below shows the annual net assets of Caladrius Biosciences Inc. from 2016 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | $32.50 Million | +56.11% |
| 2019-12-31 | $20.82 Million | -44.82% |
| 2018-12-31 | $37.73 Million | -25.31% |
| 2017-12-31 | $50.51 Million | +934.15% |
| 2016-12-31 | $4.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Caladrius Biosciences Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2076119000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
- The company has 2.2% of equity in treasury stock, representing shares repurchased from the open market.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | 0.06% |
| Treasury Stock | $708.00K | 2.18% |
| Other Components | $458.74 Million | 1411.67% |
| Total Equity | $32.50 Million | 100.00% |
Caladrius Biosciences Inc. Competitors by Market Cap
The table below lists competitors of Caladrius Biosciences Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank Rakyat Indonesia Agroniaga
JK:AGRO
|
$35.48 Million |
|
LWSABAH
KLSE:5328
|
$35.49 Million |
|
Duksung
KO:004830
|
$35.51 Million |
|
Exicom Tele-Systems Limited
NSE:EXICOM
|
$35.51 Million |
|
PRICELINE GROUP (PCE1.SG)
STU:PCE1
|
$35.43 Million |
|
GUNOSY INC.
F:6GU
|
$35.42 Million |
|
PT Wintermar Offshore Marine Tbk
F:W6O
|
$35.40 Million |
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
$35.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Caladrius Biosciences Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 20,816,000 to 32,496,000, a change of 11,680,000 (56.1%).
- Net loss of 8,150,000 reduced equity.
- Share repurchases of 18,728,000 reduced equity.
- Other factors increased equity by 38,558,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.15 Million | -25.08% |
| Share Repurchases | $18.73 Million | -57.63% |
| Other Changes | $38.56 Million | +118.65% |
| Total Change | $- | 56.11% |
Book Value vs Market Value Analysis
This analysis compares Caladrius Biosciences Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Caladrius Biosciences Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-25.08%) is above the historical average (-156.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -668.65% | 0.00% | 0.00x | 10.96x | $-33.14 Million |
| 2017 | 45.50% | 0.00% | 0.00x | 1.25x | $17.93 Million |
| 2018 | -42.85% | 0.00% | 0.00x | 1.18x | $-19.94 Million |
| 2019 | -93.01% | 0.00% | 0.00x | 1.30x | $-21.44 Million |
| 2020 | -25.08% | 0.00% | 0.00x | 1.11x | $-11.40 Million |
Industry Comparison
This section compares Caladrius Biosciences Inc.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Caladrius Biosciences Inc. (0HS8) | $98.67 Million | -668.65% | 0.04x | $35.46 Million |
| Nyfosa AB (0A0K) | $13.33 Billion | 16.69% | 1.39x | $961.70 Million |
| Tethys Oil AB (0A1V) | $256.60 Million | 6.51% | 0.11x | $122.95 Million |
| High Templar Tech Limited (0A2T) | $12.04 Billion | -3.01% | 0.06x | $258.24 Million |
| Strategy Inc (0A7O) | $605.73 Million | 3.00% | 0.54x | $37.86 Billion |
| NACON SASU (0A9N) | $40.77 Million | 2.41% | 0.74x | $7.35 Million |
| Antin Infrastructure Partners (0AA5) | $32.26 Million | 152.50% | 1.23x | $579.46 Million |
| Truecaller AB Series B (0AA7) | $145.93 Million | -10.64% | 1.99x | $271.46 Million |
| Brockhaus Technologies AG (0AAW) | $315.34 Million | 15.55% | 1.46x | $75.78 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $39.07 Million | -39.37% | 0.22x | $71.96 Million |
| Kalray S.A. (0ABT) | $54.02 Million | -28.78% | 0.63x | $33.84 Million |